European Stocks Trade Mixed as Confidence in Germany Drops
at The Street - 2 hrs ago
European stock markets are mixed as a drop in German business confidence stokes new concerns about the pace of economic recovery in Europe.
Ryan & Maniskas, LLP Announces Investigation of Sigma-Aldrich Corporation
PR Newswire - Tue Sep 23, 9:45AM CDT
Ryan & Maniskas, LLP is investigating potential claims against the board of directors of Sigma-Aldrich Corporation ("Sigma-Aldrich" or the "Company"
Polycystic Ovarian Syndrome Therapeutics Pipeline Review 2014 - 6 Companies & 9 Drug Profiles
M2 - Tue Sep 23, 9:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sgjg9w/polycystic) has announced the addition of the "Polycystic Ovarian Syndrome - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Polycystic Ovarian Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycystic Ovarian Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Euroscreen S.A. - Neurocrine Biosciences, Inc. - Merck KGaA - EffRx Pharmaceuticals S.A. - Crinetics Pharmaceuticals, Inc. Drug Profiles - choriogonadotropin alfa - AZD-4901 - ESN-364 - Small Molecule to Antagonize GnRH for Endometriosis, Uterine Fibroids, and Oncology - metformin hydrochloride - Synthetic Peptide to Target GPR54 for Womens Health, Male Health and Oncology - Synthetic Peptide for Metabolic Syndrome and Polycystic Ovarian Syndrome - Small Molecules to Inhibit KISS-1R For Polycystic Ovarian Syndrome - Small Molecules to Inhibit PAI-1 for Thromboembolic Disease, PCOS and Alopecia For more information visit http://www.researchandmarkets.com/research/sgjg9w/polycystic
SIGMA-ALDRICH INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sigma-Aldrich Corporation
PR Newswire - Mon Sep 22, 5:58PM CDT
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF"
Business Highlights
By The Associated Press - AP - Mon Sep 22, 5:00PM CDT
___
EQUITY ALERT: Rosen Law Firm Announces Investigation of Sigma-Aldrich Corporation Concerning its Proposed Sale to Merck KGaA
Business Wire - Mon Sep 22, 3:01PM CDT
The Rosen Law Firm, P.A. announces that it is investigating the Board of Directors of Sigma-Aldrich Corporation (NASDAQ:SIAL) for possible breaches of fiduciary duty and other violations of state law by failing to adequately shop Sigma-Aldrich to maximize shareholder value before agreeing to be acquired by Merck KGaA.
SIGMA-ALDRICH INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Sigma-Aldrich Corp. Over the Proposed Sale of the Company to Merck KGaA - SIAL
PR Newswire - Mon Sep 22, 12:08PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Sigma-Aldrich Corp. ("Sigma-Aldrich" or the "Company"
SIGMA-ALDRICH SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Merck KGaA
Business Wire - Mon Sep 22, 10:27AM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Sigma-Aldrich Corporation ("Sigma-Aldrich"
Block & Leviton LLP Investigates Sigma-Aldrich Corporation for Possible Breaches of Fiduciary Duty in Connection with Its Merger with Merck KGaA
PR Newswire - Mon Sep 22, 8:51AM CDT
Block & Leviton LLP (www.blockesq.com), a Boston-based law firm representing investors nationwide, has commenced an investigation into possible breaches of fiduciary duty by the Board of Directors of Sigma-Aldrich Corporation ("Sigma-Aldrich" or the "Company"
German Merck to buy St. Louis-based Sigma-Aldrich
By DAVID McHUGH - AP - Mon Sep 22, 8:03AM CDT
FRANKFURT, Germany (AP) — German drug company Merck says it has agreed to buy St. Louis-based chemical firm Sigma-Aldrich Corp. for $17 billion in a deal Merck says will strengthen its business in chemicals and laboratory equipment.
EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time
CNW Group - Fri Sep 19, 3:10AM CDT
EMD Serono, a subsidiary of Merck KGaA, Darmstadt, Germany, today announced the first recipients of the Grant for Growth Innovation (GGI) for 2014. The awards were announced during a Satellite Symposium organized by EMD Serono at the 53rd European Society for Paediatric Endocrinology (ESPE) Meeting currently taking place in Dublin, Ireland.
Merck KGaA Strengthens Executive Board
CNW Group - Thu Sep 18, 10:39AM CDT
Merck KGaA today announced that the Board of Partners has promoted Stefan Oschmann (57) to the position of Deputy CEO and Vice Chairman of the Executive Board. Concurrently, Belén Garijo (54) was appointed to the Executive Board to take over leadership for the Pharma business. The management changes will become effective as of January 1, 2015.
EMD Serono and Sutro Biopharma to Partner on Development of Antibody Drug Conjugates
Business Wire - Wed Sep 17, 7:01AM CDT
--Sutro's Xpress CF and Xpress CF+ platforms to be utilized to develop antibody drug conjugates for multiple undisclosed targets
Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates
PR Newswire - Wed Sep 17, 7:00AM CDT
Sutro Biopharma, a biopharmaceutical company developing antibody drug conjugates and bispecific antibodies, and the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, which operates as EMD Serono in the United States and Canada, today announced a collaboration and license agreement to develop antibody drug conjugates (ADCs). ADCs are composed of an antibody linked to a cytotoxic drug. The antibody is thought to specifically target and deliver the cytotoxic drug to the cancer cells.
The Zacks Analyst Blog Highlights: Merck KGaA, Lannett, Avanir Pharmaceuticals, Anacor Pharmaceuticals and Helen of Troy
PR Newswire - Tue Sep 16, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Merck KGaA (OTC:MKGAF-Free Report), Lannett Company, Inc. (NYSE:LCI-Free Report), Avanir Pharmaceuticals, Inc. (Nasdaq:AVNR-Free Report), Anacor Pharmaceuticals, Inc. (Nasdaq:ANAC-Free Report) and Helen of Troy Limited (Nasdaq:HELE-Free Report).
EMD Millipore Recognized for Technologically Advanced Products by R&D Magazine
Business Wire - Mon Sep 15, 7:00AM CDT
EMD Millipore, the Life Science division of Merck KGaA, announced it has received two R&D Magazine 100 Awards for innovative products released to market in 2014. The 52nd Annual R&D Awards recognize the 100 most technologically significant products introduced into the marketplace over the past year.
Merck KGaA Discontinues Clinical Development Program of Tecemotide as a Monotherapy in Stage III Non-Small Cell Lung Cancer
CNW Group - Fri Sep 12, 9:54AM CDT
Merck KGaA, Darmstadt, Germany, announced today that its biopharmaceutical division will discontinue the clinical development program of its investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) as a monotherapy in Stage III non-small cell lung cancer (NSCLC).
EMD Serono Honors Recipients of the Second Annual EUR 1 Million Grant for Multiple Sclerosis Innovation
PR Newswire - Fri Sep 12, 7:00AM CDT
EMD Serono Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, today announced the recipients of the second annual Grant for Multiple Sclerosis Innovation (GMSI) at the 2014 Joint ACTRIMS-ECTRIMS Meeting of the Americas Committee for Treatment and Research in MS (ACTRIMS) and European Committee for Treatment and Research in MS (ECTRIMS), taking place September 10-13, in Boston, U.S.A.